
EHA 2025: BMS-986458 Shows Clinical Promise in FL and DLBCL
As precision medicine continues to redefine therapeutic strategies in hematologic malignancies, novel approaches such as targeted protein degradation are rapidly gaining traction. Among the emerging agents in this space is BMS-986458 (Bristol Myers Squibb …